Please use this identifier to cite or link to this item:
|Title:||Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: Analysis of clinical features and outcomes from the Asia Lymphoma study group||Authors:||Kim, S.J.
|Keywords:||Extranodal NK/T-cell lymphoma
|Issue Date:||16-Nov-2013||Citation:||Kim, S.J., Jung, H.A., Chuang, S.-S., Hong, H., Guo, C.-C., Cao, J., Hong, X.-N., Suzuki, R., Kang, H.J., Won, J.H., Chng, W.-J., Kwong, Y.-L., Suh, C., Song, Y.-Q., Zhu, J., Tay, K., Lim, S.T., Suzumiya, J., Lin, T.-Y., Kim, W.S. (2013-11-16). Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: Analysis of clinical features and outcomes from the Asia Lymphoma study group. Journal of Hematology and Oncology 6 (1) : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1756-8722-6-86||Abstract:||Background: The gastrointestinal (GI) tract is one of the most common extranasal sites in extranodal NK/T-cell lymphoma (ENKTL). However, data regarding ENKTL involving the GI tract are relatively scarce. Thus, we performed a multicenter, multinational retrospective study to analyze clinical features and treatment outcomes of ENKTL involving the GI tract. Patients and methods. Patients with ENKTL involving the GI tract diagnosed in twelve participating centers between 1991 and 2012 were retrospectively analyzed from five Asian countries. Results: The analysis of 81 patients with ENKTL involving the GI tract revealed that more than 60% of patients presented as advanced disease with B symptoms. 55 patients (68%) had GI manifestations including abdominal pain (n = 26, 32%), GI tract bleeding (n = 17, 21%) and bowel perforation (n = 12, 15%). The most common GI site was the small intestine, including the jejunum and ileum (n = 57, 70.3%). There were 34 patients (42%) who received systemic chemotherapy while 33 patients (41%) underwent surgery plus chemotherapy. However, 35 patients (43%) died due to disease progression, and treatment-related mortality including sepsis occurred in 17 patients (21%). Thus, the median overall survival was 7.8 months (95% Confidence interval: 3.9 - 11.7 months). Patients who could undergo surgery plus chemotherapy showed a trend of better survival than those treated with chemotherapy alone. Conclusion: Overall, the data indicated that ENKTL involving the GI tract has a dismal prognosis despite active treatment including chemotherapy and surgery. Thus, more effective treatment strategies are required for this disease entity. © 2013 Kim et al.; licensee BioMed Central Ltd.||Source Title:||Journal of Hematology and Oncology||URI:||http://scholarbank.nus.edu.sg/handle/10635/126810||ISSN:||17568722||DOI:||10.1186/1756-8722-6-86|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.